Edeanya Agbese1, Douglas L Leslie1, Ajay Manhapra1, Robert Rosenheck1. 1. Department of Public Health Sciences and Center for Applied Studies in Health Economics, Penn State College of Medicine, Hershey, Pennsylvania (Agbese, Leslie); U.S. Department of Veterans Affairs (VA) VISN 1 New England Mental Illness Research and Education Center, West Haven, Connecticut, and Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut (Manhapra, Rosenheck); Hampton VA Medical Center, Hampton, Virginia (Manhapra).
Abstract
OBJECTIVE: This study examined the temporal relationship between early discontinuation of buprenorphine treatment and health care expenditures before and after treatment initiation. METHODS: MarketScan commercial claims for patients who initiated buprenorphine for opioid use disorder in 2013 and had continuous insurance for the subsequent 12 months (N=6,444) were used to examine the relationship between treatment retention and health care expenditures before and after buprenorphine initiation. Analysis of covariance and generalized linear models (with gamma distribution/log link) were used to compare expenditures across four buprenorphine-retention groups (0-3, 3-6, 6-12, and 12 or more months). RESULTS: Average total health care expenditures in the 3 months prior to buprenorphine initiation ranged from a high of $7,588 among those with the shortest retention to $4,929 among those with the longest retention (p<0.001). In the 12 months after buprenorphine initiation, total health care expenditures averaged $26,332 per year, with $2,916 (11.1%) in out-of-pocket expenditures. Average annual expenditures for medication were highest among patients with the longest buprenorphine retention, and total health care expenditures were highest among those with the shortest retention. Expenditures for health care services other than medication were highest among those with early discontinuation both before the initiation of buprenorphine and during the initial period after initiation but not in subsequent quarters. CONCLUSIONS: Poorer treatment retention among privately insured adults was associated with greater clinical and financial burdens that preceded and continued during the period shortly following treatment initiation, suggesting that cost burdens may contribute to poor retention among privately insured adults.
OBJECTIVE: This study examined the temporal relationship between early discontinuation of buprenorphine treatment and health care expenditures before and after treatment initiation. METHODS: MarketScan commercial claims for patients who initiated buprenorphine for opioid use disorder in 2013 and had continuous insurance for the subsequent 12 months (N=6,444) were used to examine the relationship between treatment retention and health care expenditures before and after buprenorphine initiation. Analysis of covariance and generalized linear models (with gamma distribution/log link) were used to compare expenditures across four buprenorphine-retention groups (0-3, 3-6, 6-12, and 12 or more months). RESULTS: Average total health care expenditures in the 3 months prior to buprenorphine initiation ranged from a high of $7,588 among those with the shortest retention to $4,929 among those with the longest retention (p<0.001). In the 12 months after buprenorphine initiation, total health care expenditures averaged $26,332 per year, with $2,916 (11.1%) in out-of-pocket expenditures. Average annual expenditures for medication were highest among patients with the longest buprenorphine retention, and total health care expenditures were highest among those with the shortest retention. Expenditures for health care services other than medication were highest among those with early discontinuation both before the initiation of buprenorphine and during the initial period after initiation but not in subsequent quarters. CONCLUSIONS: Poorer treatment retention among privately insured adults was associated with greater clinical and financial burdens that preceded and continued during the period shortly following treatment initiation, suggesting that cost burdens may contribute to poor retention among privately insured adults.
Entities:
Keywords:
Adherence; Buprenorphine; Drug abuse; Drug treatment/psychopharmacology; Opioid use disorder
Authors: Alene Kennedy-Hendricks; Cameron J Schilling; Alisa B Busch; Elizabeth A Stuart; Haiden A Huskamp; Mark K Meiselbach; Colleen L Barry; Matthew D Eisenberg Journal: J Gen Intern Med Date: 2021-08-17 Impact factor: 5.128
Authors: Evan S Cole; Coleman Drake; Ellen DiDomenico; Michael Sharbaugh; Joo Yeon Kim; Dylan Nagy; Gerald Cochran; Adam J Gordon; Walid F Gellad; Janice Pringle; Jack Warwick; Chung-Chou H Chang; Julie Kmiec; David Kelley; Julie M Donohue Journal: Drug Alcohol Depend Date: 2021-02-16 Impact factor: 4.492